Rsv Disease

During their first season in use, respiratory syncytial virus vaccines reduced the risk for RSV-associated hospitalization by 75% among adults aged 60 years or older, according to a study.

Palivizumab was consistently found to be cost-effective as prophylaxis for respiratory syncytial virus disease among neonates on four continents, according to a study presented at the Pediatric Academic Societies Meeting.

Multiple prevention tools against respiratory syncytial virus in children became available in the United States this year.

The monoclonal antibody nirsevimab prevented hospitalizations for respiratory syncytial virus-associated disease among infants “in conditions that approximated real-world settings,” researchers wrote in The New England Journal of Medicine.

Young children with respiratory syncytial virus were hospitalized at a higher rate in the years after the start of the COVID-19 pandemic than in the six seasons before it, according to a study in JAMA Pediatrics.

Researchers identified 16 predictors of infant hospitalization for respiratory syncytial virus and developed a model that clinicians can use to predict an infant’s risk, according to findings published in The Lancet Digital Health.

Fewer than one in four U.S. adults are concerned about influenza, COVID-19 or respiratory syncytial virus infection, according to an annual survey administered by the National Foundation for Infectious Diseases.